International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
April 18 2018 - 8:30AM
InvestorsHub NewsWire
Carlsbad, CA -- April 18, 2018 -- InvestorsHub
NewsWire -- International Stem Cell Corporation (OTCQB:ISCO)
(www.internationalstemcell.com)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company developing stem cell-based therapies and
biomedical products, announced today that its Chief Scientific
Officer, Russell Kern, PhD, will deliver a platform presentation on
the Company's Parkinson's disease clinical trial at the American
Academy of Neurology 70th Annual Meeting at the Los Angeles
Convention Center in Los Angeles, CA.
Session Date: Tuesday April
24, 2018
Session
title: Session
S26: Movement Disorders: Parkinson's Disease Clinical
Trials
Presentation
Time: 3:42
PM
Presentation title:
Interim
Clinical Assessment of a Neural Stem Cell Based Therapy for
Parkinson's Disease
About Parkinson's
disease
Parkinson's disease (PD) is a degenerative
disorder of the central nervous system mainly affecting the motor
system. The motor symptoms of Parkinson's disease result from the
death of dopamine-generating cells in the substantia nigra, a
region of the midbrain. Early in the course of the disease, the
most obvious symptoms are movement-related; these symptoms include
shaking, rigidity, slowness of movement and difficulty with walking
and gait. Later, thinking and behavioral problems may arise, with
dementia commonly occurring in the advanced stages of the disease,
and depression is the most common psychiatric symptom. Parkinson's
disease is more common in older people, with most cases occurring
after the age of 50.
Currently, medications typically used in the
treatment of Parkinson's, L-DOPA and dopamine agonists, improve the
early symptoms of the disease. As the disease progresses and
dopaminergic neurons continue to be lost, the drugs eventually
become ineffective while at the same time frequently producing a
complication marked by involuntary writhing movements. In 2013 PD
resulted in about 103,000 deaths globally, up from 44,000 deaths in
1990.
About ISC-hpNSC®
International Stem Cell Corporation's
proprietary ISC-hpNSC® consists of a highly pure population of
neural stem cells derived from human parthenogenetic stem cells.
ISC-hpNSC® is a suspension of clinical grade cells manufactured
under cGMP conditions that have undergone stringent quality control
measures and are clear of any microbial and viral contaminants.
Preclinical studies in rodents and non-human primates have shown
improvement in Parkinson's disease symptoms and increase in brain
dopamine levels following the intracranial administration of
ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and cell
replacement to the dying dopaminergic neurons of the recipient PD
brain. Additionally, ISC-hpNSC® is safe, well tolerated and does
not cause adverse events such as dyskinesia, systemic toxicity or
tumors in preclinical models. International Stem Cell Corporation
believes that ISC-hpNSC® may have broad therapeutic applications
for many neurological diseases affecting the brain, the spinal cord
and the eye.
About International Stem Cell
Corporation
International Stem Cell Corporation (ISCO) is
focused on the therapeutic applications of human parthenogenetic
stem cells (hpSCs) and the development and commercialization of
cell-based research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary
Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com.
To
subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like
our Facebook page or follow us on Twitter for company updates and
industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated
developments, expected results and timing of clinical studies,
potential applications of ISC-hpNSC® to other diseases, progress of
research and development initiatives, and other opportunities for
the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any
statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates,") should also be
considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products (including clinical trial
results that differ from expectations based on earlier studies),
regulatory approvals, need and ability to obtain future capital,
application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company's business,
particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update
forward-looking statements.
Contacts:
International Stem Cell
Corporation
Russell
A. Kern, PhD
Phone:
760-940-6383
Email: ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Sep 2023 to Sep 2024